Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q35617324)
Watch
English
Viral hepatitis C.
scientific article published on December 2003
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
14697814
retrieved
9 August 2017
review article
1 reference
stated in
Europe PubMed Central
title
Viral hepatitis C.
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
14697814
retrieved
9 August 2017
main subject
viral hepatitis
1 reference
based on heuristic
inferred from title
author
Thierry Poynard
object named as
Thierry Poynard
series ordinal
1
0 references
author name string
Man-Fung Yuen
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
14697814
retrieved
9 August 2017
Vlad Ratziu
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed ID
14697814
retrieved
9 August 2017
Ching Lung Lai
series ordinal
4
1 reference
stated in
Europe PubMed Central
PubMed ID
14697814
retrieved
9 August 2017
language of work or name
English
0 references
publication date
1 December 2003
1 reference
stated in
Europe PubMed Central
PubMed ID
14697814
retrieved
9 August 2017
published in
The Lancet
1 reference
stated in
Europe PubMed Central
PubMed ID
14697814
retrieved
9 August 2017
volume
362
1 reference
stated in
Europe PubMed Central
PubMed ID
14697814
retrieved
9 August 2017
issue
9401
1 reference
stated in
Europe PubMed Central
PubMed ID
14697814
retrieved
9 August 2017
page(s)
2095-2100
1 reference
stated in
Europe PubMed Central
PubMed ID
14697814
retrieved
9 August 2017
cites work
Hepatitis C virus infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Viral hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatocellular carcinoma: an epidemiologic view
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rising incidence of hepatocellular carcinoma in the United States
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Modeling the hepatitis C virus epidemic in France
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparing the public health burden of chronic hepatitis C and HIV infection in France
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Fibrosis in patients with chronic hepatitis C: detection and significance
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Histological features predictive of liver fibrosis in chronic hepatitis C infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The long-term pathological evolution of chronic hepatitis C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Impact of alcohol on the histological and clinical progression of hepatitis C infection.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sex and hepatic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Contribution of obesity to hepatitis C-related fibrosis progression
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Extrahepatic manifestations of hepatitis C among United States male veterans
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Psychiatric disorders among veterans with hepatitis C infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Peginterferon alfa-2a in patients with chronic hepatitis C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cytokines and chemokines in the immune response to hepatitis C infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Standardization of hepatitis C virus RNA quantification
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sampling variability of liver fibrosis in chronic hepatitis C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Appropriateness of liver biopsy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Diagnosing fibrosis in hepatitis C: Is the pendulum swinging from biopsy to blood tests?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon therapy prolonged life expectancy among chronic hepatitis C patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of acute hepatitis C with interferon alfa-2b
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0140-6736(03)15109-4
1 reference
stated in
Europe PubMed Central
PubMed ID
14697814
retrieved
9 August 2017
PubMed ID
14697814
1 reference
stated in
Europe PubMed Central
PubMed ID
14697814
retrieved
9 August 2017
ResearchGate publication ID
8939887
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit